Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Muscle-invasive Bladder Cancer × durvalumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 73 Lung Neoplasms 35 Carcinoma, Hepatocellular 34 Small Cell Lung Carcinoma 24 Cholangiocarcinoma 18 Urinary Bladder Neoplasms 16 Neoplasms 14 Breast Neoplasms 14 Squamous Cell Carcinoma of Head and Neck 12 Colorectal Neoplasms 12 Triple Negative Breast Neoplasms 11 Biliary Tract Neoplasms 10 Liver Neoplasms 9 Esophageal Neoplasms 8 Stomach Neoplasms 7 Pancreatic Neoplasms 7 Ovarian Neoplasms 7 Neoplasm Metastasis 7 Head and Neck Neoplasms 7 Recurrence 6 Prostatic Neoplasms 6 Melanoma 6 Carcinoma, Transitional Cell 6 Carcinoma, Renal Cell 6 Bile Duct Neoplasms 6 Neoplasms by Site 5 Adenocarcinoma 5 Uterine Cervical Neoplasms 4 Respiratory Tract Neoplasms 4 Mesothelioma, Malignant 4

Interventions

tremelimumab 1 pembrolizumab 1 enfortumab vedotin 1 durvalumab 1 Watchful Waiting 1 Radiotherapy 1 Palliative Care 1 Drug Therapy 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03234153 2020-06-17

NITIMIB

Insel Gruppe AG, University Hospital Bern

Phase 2 Terminated

Muscle-invasive Bladder Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡